國家衛生研究院 NHRI:Item 3990099045/11553
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 917334      在线人数 : 1434
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/11553


    题名: Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic oesophageal cancer;a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
    作者: Muro, K;Lordick, F;Tsushima, T;Pentheroudakis, G;Baba, E;Lu, Z;Cho, BC;Nor, IM;Ng, M;Chen, LT;Kato, K;Li, J;Ryu, MH;Zamaniah, WIW;Yong, WP;Yeh, KH;Nakajima, TE;Shitara, K;Kawakami, H;Narita, Y;Yoshino, T;Van Cutsem, E;Martinelli, E;Smyth, EC;Arnold, D;Minami, H;Tabernero, J;Douillard, JY
    贡献者: National Institute of Cancer Research
    摘要: The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of oesophageal cancer was published in 2016, and covered the management and treatment of local/locoregional disease, limited disease, locally advanced disease and the management of advanced/metastatic disease. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting immediately after the JSMO Annual Meeting in 2018. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic oesophageal cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic oesophageal cancer representing the oncological societies of Japan (JSMO), China (CSCO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.
    日期: 2019-01
    關聯: Annals of Oncology. 2019 Jan;30(1):34-43.
    Link to: http://dx.doi.org/10.1093/annonc/mdy498
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000459677700008
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85060182066
    显示于类别:[陳立宗] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    PUB30475943.pdf463KbAdobe PDF273检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈